Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.

被引：17

作者：

Grunwald, Viktor

Powles, Thomas

Kopyltsov, Evgeny

Kozlov, Vadim

Gordoa, Teresa Alonso

Eto, Masatoshi

Hutson, Thomas E.

Motzer, Robert J.

Winquist, Eric

Maroto-Rey, Pablo

Keam, Bhumsuk

Procopio, Giuseppe

Wong, Shirley

Melichar, Bohuslav

Rolland, Frederic

Oya, Mototsugu

Rodriguez-Lopez, Karla

Saito, Kenichi

Smith, Alan D.

Porta, Camillo

机构：

[1] Univ Hosp Essen, Essen, Germany

[2] Royal Free NHS Trust, London, England

[3] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia

[4] State Budgetary Hlth Care Inst Novosibirsk Reg Cl, Novosibirsk, Russia

[5] Hosp Univ Ramon y Cajal, Madrid, Spain

[6] Kyushu Univ, Fukuoka, Japan

[7] Texas Oncol, Dallas, TX USA

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Western Univ, London, ON, Canada

[10] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[11] Seoul Natl Univ Hosp, Seoul, South Korea

[12] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy

[13] Western Hlth, St Albans, Vic, Australia

[14] Palacky Univ Med Sch & Teaching Hosp, Olomouc, Czech Republic

[15] Ctr Lutte Canc Nantes, Ctr Rene Gauducheau, St Herblain, France

[16] Keio Univ, Sch Med, Tokyo, Japan

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Eisai Inc, Woodcliff Lake, NJ USA

[19] Eisai Ltd, Hatfield, Herts, England

[20] San Matteo Univ Hosp Fdn, Pavia, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4560

引用

页数：3